Onchilles Pharma Inc. has obtained IND approval from the FDA for N-17350, enabling initiation of first-in-human studies in patients with advanced solid tumors. The study will enroll patients in the U.S. and Australia with advanced solid tumors.
Metabolic dysfunction-associated steatohepatitis (MASH) involves hepatic steatosis, inflammation, and fibrosis driven in part by hepatic stellate cell (HSC) activation. Dual inhibition of ACLY and ACSS2 restricts complementary hepatic sources of acetyl-CoA, a key driver of lipogenesis and MASH pathology.
Certain chemical compounds can disable the bacterial immune systems that protect them from viruses, making the bacteria vulnerable to infection. Scientists at Indiana University have discovered a promising compound that works in different types of bacteria and could be used to develop potent and diverse phage therapies against bacterial infections, ultimately giving clinicians more options against antibiotic resistance.
Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized peptide-lipid drug conjugates comprising a neuromedin U NMU2 receptor agonist peptide. They are reported to be useful for the treatment of obesity.
Astrazeneca AB has identified new quinazoline derivatives acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. As such, they are described as potentially useful for the treatment of colitis, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, schizophrenia, thrombosis and Alzheimer’s disease among others.
Uppthera Inc. has patented new proteolysis targeting chimera (PROTAC) compounds comprising cereblon E3 ubiquitin ligase-binding moiety covalently linked to Aurora kinase A (AURKA; ARK1)-targeting moiety. They are reported to be useful for the treatment of cancer.
Alterome Therapeutics Inc. has divulged substituted pyrido[4,3-d]pyrimidines acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disorder with unknown etiology, leading to loss of upper and lower motor neurons, muscle paralysis, and, eventually, death. In the majority of cases (about 90%), the disease is sporadic, while the rest have a genetic component.
Recent studies found that some members of the olfactory receptor (OR) family can be activated by peptides and hormone proteins to mediate specific physiological processes, in addition to their roles in sensing odor molecules to mediate olfaction.
RSS
